Abbott Laboratories announced strong second-quarter results for fiscal year 2026, with sales increasing by 13% year-over-year, and raised its full-year profit outlook, increasing its adjusted diluted EPS guidance range for fiscal year 2026 to $5.45 to $5.60. The company's diagnostics division sales grew by 42% to $3.09 billion, exceeding expectations.

In contrast, Danaher Corporation's second-quarter revenue grew by 5.5% to $6.3 billion, but it lowered its full-year core revenue growth outlook, reducing the upper end from 6% to 4% and maintaining the lower end at 3%. Previously, the company's biotechnology business revenue fell short of expectations, causing its stock price to drop by 11%. Bank of America maintained its "buy" rating for Danaher but lowered its price target from $270 to $230.